



**eLITERATURE  
REVIEW**

**eMedicalDermatology Review**

Presented by  
The Johns Hopkins University  
School of Medicine, The Institute  
for Johns Hopkins Nursing and the  
University of Tennessee College  
of Pharmacy

Supported by an Educational Grant  
from Centocor, Inc.

## Podcast POST-TEST & EVALUATION

**October 2007 Edition - ACPE Program #064-999-07-254-L01-P**

**Please Complete the Post-test and Evaluation and Mail/Fax to:**

### **THE UNIVERSITY OF TENNESSEE**

**Health Science Center  
College of Pharmacy  
213 Conference Center  
600 Henley Street  
Knoxville, TN 37996**

Tel: (865) 974-6605  
Fax: (865) 974-2987

A statement of CE credit will be mailed within 4 weeks  
of successful completion and evaluation of the program.

Name \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_ Zip: \_\_\_\_\_

Phone Number: \_\_\_\_\_

License Number: \_\_\_\_\_

**Post-test Question 1**

Which factor(s) is most commonly associated with the development of complications in infantile hemangiomas?

**Answer Choices for Question 1**

- A. Prematurity
- B. Being female
- C. Patient age
- D. Hemangioma morphology
- E. Hemangioma pattern

**Post-test Question 2**

Which risk factor is most commonly associated with ulceration in hemangiomas?

**Answer Choices for Question 2**

- A. Diaper area location
- B. Large size (>40 cm<sup>2</sup>)
- C. Segmental pattern
- D. Superficial morphology
- E. Proliferative phase

**Post-test Question 3**

Extracutaneous complications of hemangiomas are most likely to be associated with which of the following hemangioma patterns?

**Answer Choices for Question 3**

- A. Focal
- B. Multifocal
- C. Segmental
- D. Subcutaneous
- E. Superficial

**Post-test Question 4**

Initial management of ulcerated hemangiomas should include which of the following?

**Answer Choices for Question 4**

- A. Wound care management
- B. Pulsed dye laser
- C. Human platelet-derived growth factor
- D. Imiquimod
- E. Surgical debridement

**Post-test Question 5**

Although there are no rigorous evidence based studies and no FDA approved treatments, substantial data and experience supports the use of which of the following modalities in the treatment of recalcitrant ulcerations in hemangiomas.

**Answer Choices for Question 5**

- A. Human platelet-derived growth factor
- B. Topical imiquimod
- C. Pulsed dye laser
- D. Surgical debridement
- E. Topical corticosteroids

### **Post-test Question 6**

Effective management strategies for ulcerated hemangiomas might include which of the following?

#### **Answer Choices for Question 6**

- A. Local wound care
- B. Oral analgesics
- C. Oral corticosteroids
- D. Parent counseling
- E. All of the above

## **EVALUATION**

### **Evaluation Question 1**

This program met my overall objectives.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

### **Evaluation Question 2**

This program identifies the epidemiologic and clinical risk factors for development of both hemangiomas and hemangiomas at greatest risk for complications.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

### **Evaluation Question 3**

This program defines the clinical patterns, anatomic depth, location, and other risk factors for development of ulcerations in hemangiomas.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

### **Evaluation Question 4**

This program designs a comprehensive management plan for treating ulcerated hemangiomas.

- A. Strongly Agree
- B. Somewhat Agree
- C. Neutral
- D. Somewhat Disagree
- E. Strongly Disagree

**Evaluation Question 5**

What is your overall opinion of this program as it applies to your clinical practice?

- A. Very useful
- B. Somewhat useful
- C. Neutral
- D. Not very useful
- E. Not at all useful

**Evaluation Question 6**

In what way(s) can this program be improved?

---

---

---

**Evaluation Question 7**

CME activities must be "free of commercial bias for or against any product." In this regard, did you perceive any commercial influence in this web-based presentation?

- A. Yes (please explain)

---

---

---

- B. No

**Evaluation Question 8**

Did the author(s) disclose discussion of off-label drugs and/or devices?

- A. Yes
- B. No (please explain)

---

---

---

C. N/A - There was no discussion of off-label drugs and/or devices

**Evaluation Question 9**

Would you like to receive information on other CME activities?

A. Yes. My email address is:

---

B. No, thank you.

**Evaluation Question 10**

Enter the number of hours it took you to complete this course (e.g., 0.5, 1.25, etc.):

---